About this trial

Fibromyalgia is characterized by altered pain processing, including impaired descending pain inhibition and central sensitization. While both mechanisms have been independently associated with disease severity, their interrelationship remains unclear. This cross-sectional study aims to investigate whether central sensitization symptoms mediate the relationship between conditioned pain modulation and fibromyalgia impact.

Eligibility criteria

Qualifiers

Having received a diagnosis of fibromyalgia according to the 2016 ACR diagnostic criteria

Female patients aged 18-65

Being literate

Having signed the informed consent form upon agreeing to participate in the study

Disqualifiers

Being under 18 or over 65 years of age

Having any condition that may lower the pain threshold or cause chronic pain (Rheumatoid Arthritis, Ankylosing Spondylitis, systemic inflammatory diseases, malignancies, etc.)

Any neurological condition (stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, central nervous system malignancies…)

Peripheral artery disease

Trial design

Treatments tested in this trial

  • Quantitative Sensory Tests(QST) protocol
  • Clinical Scales

Treatment groups

82 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

Lead sponsor